Table 1. Patient Demographic and Clinical Characteristics.
| Characteristic | No. (%) | P valuea | |
|---|---|---|---|
| Methylated MGMT promoter (n = 229) | Unmethylated MGMT promoter (n = 182) | ||
| Age, median (IQR), y | 43 (35-53) | 44 (31-56) | .69 |
| Sex | |||
| Female | 96 (42) | 77 (42) | .94 |
| Male | 133 (58) | 105 (58) | |
| Molecular class | |||
| IDH–wild type | 56 (25) | 79 (43) | <.001 |
| IDH-mutant and non-codeleted | 79 (35) | 70 (39) | |
| IDH-mutant and codeleted | 94 (41) | 33 (18) | |
| Grade | |||
| II | 78 (34) | 72 (40) | .25 |
| III | 151 (66) | 110 (60) | |
| Chemotherapy | |||
| Yes | 157 (69) | 131 (72) | .45 |
| No | 72 (31) | 51 (28) | |
| Radiotherapy | |||
| Yes | 135 (59) | 87 (48) | .02 |
| No or unknownb | 94 (41) | 95 (52) | |
a
Calculated with the Pearson χ2 test and the Wilcoxon rank sum test.
b
For patients in the MSK-IMPACT data set, receipt of radiotherapy was inferred from subsequent surgical samples. Therefore, if no further surgeries were conducted, the patient was coded as “No or unknown” (eMethods in Supplement 1).